OSRH Graph | OSR HEALTH, INC.

OSRH Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $315.67K; Revenue including tax (m); Cost of revenue $229.06K; Research and development (m).
2026-03-31: Revenue $484.06K; Revenue including tax (m); Cost of revenue $323.78K; Research and development $113.15K.
2025-12-31: Revenue $381.27K*; Revenue including tax (m); Cost of revenue $251.56K*; Research and development $176.57K*.
2025-09-30: Revenue $627.75K; Revenue including tax (m); Cost of revenue $366.01K; Research and development (m).

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Revenue including tax	Cost of revenue	Research and development	Selling, general and administrative	Income tax	Net income
2026-06-30	$315.67K	(m)	$229.06K	(m)	$3.12M	-$439.50K	(m)
2026-03-31	$484.06K	(m)	$323.78K	$113.15K	$3.83M	-$452.31K	(m)
2025-12-31	$381.27K*	(m)	$251.56K*	$176.57K*	$6.52M*	-$534.87K*	(m)
2025-09-30	$627.75K	(m)	$366.01K	(m)	$4.07M	-$1.29M	(m)
2025-06-30	$1.14M	$1.14M	$1.10M	(m)	$5.26M	(m)	(m)
2025-03-31	$761.27K	$761.27K	$592.59K	$90.15K	$3.09M	(m)	(m)
2024-12-31	(m)	(m)	(m)	(m)	(m)	(m)	-$2.02M*
2024-09-30	$823.00K	(m)	$643.90K	(m)	$3.75M	-$139.56K	-$230.96K
2024-06-30	(m)	$881.83K	$649.51K	(m)	$3.44M	-$973.63K	-$97.30K
2024-03-31	(m)	$910.23K	$670.42K	$46.72K	$3.54M	$4.00	-$60.43K
2023-09-30	(m)	(m)	(m)	(m)	$410.43K	$129.88K	$78.18K
2023-06-30	(m)	(m)	(m)	(m)	$280.27K	$228.56K	$301.46K
2023-03-31	(m)	(m)	(m)	(m)	$278.10K	$29.32K	$110.31K
2022-09-30	(m)	(m)	(m)	(m)	$20.02K	(m)	-$20.02K
2022-06-30	(m)	(m)	(m)	(m)	$988.00	(m)	-$988.00
2022-03-31	(m)	(m)	(m)	(m)	(m)	(m)	-$126.00

Revenue and expense 6 month

Period end	Revenue	Revenue including tax	Cost of revenue	Research and development	Selling, general and administrative	Income tax	Net income
2026-06-30	$799.73K	(m)	$552.84K	$207.78K	$6.95M	-$891.82K	(m)
2025-06-30	$1.90M	$1.90M	$1.70M	$143.67K	$8.35M	(m)	(m)
2024-06-30	(m)	$1.79M	$1.32M	$91.97K	$6.98M	-$973.62K	-$157.72K
2023-06-30	(m)	(m)	(m)	(m)	$558.38K	$257.89K	$411.77K
2022-06-30	(m)	(m)	(m)	(m)	$1.11K	(m)	-$1.11K

Revenue and expense 9 month

Period end	Revenue	Cost of revenue	Research and development	Selling, general and administrative	Income tax	Net income
2025-09-30	$2.52M	$2.06M	$141.88K	$12.41M	-$1.29M	(m)
2024-09-30	$2.62M	$1.96M	$146.68K	$10.73M	-$1.11M	-$388.69K
2023-09-30	(m)	(m)	(m)	$968.81K	$387.77K	$489.95K
2022-09-30	(m)	(m)	(m)	$21.14K	(m)	-$21.14K

Revenue and expense 12 month

Period end	Revenue	Cost of revenue	Research and development	Selling, general and administrative	Income tax	Net income
2025-12-31	$2.91M	$2.31M	$318.45K	$18.93M	-$1.83M	(m)
2024-12-31	$3.53M	$2.72M	$161.16K	$12.50M	-$1.56M	-$2.41M
2023-12-31	(m)	(m)	(m)	$1.83M	$540.81K	$403.78K
2022-12-31	(m)	(m)	(m)	$35.39K	(m)	-$35.39K
2021-12-31	(m)	(m)	(m)	$3.31K	(m)	-$3.31K

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Adagio Medical Holdings, Inc. (ADGM)	United States	$0.004B
Autonomix Medical, Inc. (AMIX)	United States	$0.004B
Bluejay Diagnostics, Inc. (BJDX)	United States	$0.004B
AETHLON MEDICAL INC (AEMD)	United States	$0.005B
Beyond Air, Inc. (XAIR)	United States	$0.003B	-0.01
Vivos Therapeutics, Inc. (VVOS)	United States	$0.003B	-0.26
INTELLIGENT BIO SOLUTIONS INC. (INBS)	United States	$0.005B
NEXGEL, INC. (NXGL)	United States	$0.002B
INVO Fertility, Inc. (IVF)	United States	$0.002B	-0.71
Sonoma Pharmaceuticals, Inc. (SNOA)	United States	$0.006B	-2.59